Compare Shattuck Labs, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 431 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.91
-58.79%
4.62
Revenue and Profits:
Net Sales:
(Quarterly Results - Dec 2025)
Net Profit:
-13 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
93.06%
0%
93.06%
6 Months
156.07%
0%
156.07%
1 Year
410.0%
0%
410.0%
2 Years
-35.1%
0%
-35.1%
3 Years
101.98%
0%
101.98%
4 Years
27.23%
0%
27.23%
5 Years
-81.63%
0%
-81.63%
Shattuck Labs, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-38.55%
EBIT Growth (5y)
-25.68%
EBIT to Interest (avg)
-74.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.89
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
77.41%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.62
EV to EBIT
-5.99
EV to EBITDA
-6.40
EV to Capital Employed
43.30
EV to Sales
345.56
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-723.00%
ROE (Latest)
-58.79%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 22 Schemes (10.38%)
Foreign Institutions
Held by 34 Foreign Institutions (5.49%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-12.40
-18.60
33.33%
Interest
0.00
0.00
Exceptional Items
-0.10
-0.10
Consolidate Net Profit
-12.60
-18.70
32.62%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 0.00% vs -100.00% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 32.62% vs -5.65% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1.00
5.70
-82.46%
Operating Profit (PBDIT) excl Other Income
-47.80
-76.50
37.52%
Interest
0.00
0.00
Exceptional Items
0.00
-0.20
100.00%
Consolidate Net Profit
-48.80
-75.40
35.28%
Operating Profit Margin (Excl OI)
-51,532.00%
-14,043.90%
-3,748.81%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -82.46% vs 235.29% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 35.28% vs 13.63% in Dec 2024
About Shattuck Labs, Inc. 
Shattuck Labs, Inc.
Pharmaceuticals & Biotechnology
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of dual-sided fusion proteins. The Company has created an approach to immune modulation by designing biologics with structural characteristics. Compounds derived from its Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPa) checkpoint interaction to restore an anti-tumor immune response and to activate the cluster of differentiation 40 (CD40) costimulatory receptor to bolster an immune response. The Company's second product candidate, SL-279252, is designed to simultaneously inhibit the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction and activate the OX40 receptor.
Company Coordinates 
Company Details
1018 W. 11Th Street, Suite 100 , AUSTIN TX : 78703
Registrar Details






